TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
December 26, 2024
By
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
December 23, 2024
By
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
December 9, 2024
By
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
December 5, 2024
By
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
December 2, 2024
By
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
By
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
November 5, 2024
By
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
October 4, 2024
By
TScan Therapeutics to Participate in Upcoming Investor Conferences
August 29, 2024
By
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
By